CRLBF Stock — Cresco Labs Inc.

Up next

Next earnings call

Oct 22, 2026 Est · unconfirmed · in 9 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Neutral Momentum Weak Sentiment Bearish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 14.3 · calm Equity put/call 0.52

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −18%

below

Price vs 50-day avg +3%

above

RSI (14) 57

neutral

MACD trend Positive

52-week position 12%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return +10%

trailing

6-month return −23%

trailing

YTD return −36%

this year

Relative strength −35%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

-33% holders QoQ · +1 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

0.30% of float · ▲ +33.5% MoM · 1.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

6 holders — mid 4-yr range

Squeeze score 48

elevated · 0–100

Fundamentals

Weak

Revenue growth −9%

Y/Y

Gross margin 49%

contracting

EPS growth −73%

Y/Y

Free cash flow $37.8M

Balance sheet $362.5M

net debt

Quant / Vol

risk profile

Very High

Volatility 143%

annualized · 1-yr

Max drawdown −67%

past year

ATR 8.7%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed May 8, 2026

Revenue · 2Q 10%

Prior guidance period ended · from the Earnings Call filed May 8, 2026

Gross margins · Q2 48% – 50%

Adjusted EBITDA margins · Q2 21%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

2 · 3 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−18% Bearish

Price vs 50-day avg

+3% Bullish

RSI (14)

57 Neutral

MACD trend

Positive Bullish

52-week position

12% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $1 › 200d $1 — 200d above 50d

Institutional flow Distributing

-33% holders QoQ · +1 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

0.30% of float · ▲ +33.5% MoM · 1.3 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

6 holders — mid 4-yr range

Price context

position in its 52-week range

Range low $1 Now $1 · 12% Range high $2

vs 200-day avg -18% vs 50-day avg +3%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CRLBF Cresco Labs Inc. this stock	$301.01M	-35.8%	-9.5%	—	0.3%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$64.91B	—	—	—	0.0%
TAK Takeda Pharmaceutical Co Ltd	$56.30B	+11.5%	—	—	0.1%
GALDY Galderma Group AG/ADR	$48.51B	+0.5%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$42.85B	+16.8%	+4.3%	60.3	2.9%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

6

% held: 0.0%
Net QoQ: -135.7K sh
Top holder: ALBERT D MASON INC

Held Float

View

Short & Settlement

Short Interest Rising

Shares short

1.1M

Days to cover: 1.3d
Change: +282.1K sh

View

Short Volume

Short vol %

27%

As of: Aug 17, 2026

Short Total

View

Fails to Deliver

FTD shares

235.9K

Value: $151.0K
As of: Jul 30, 2026

View

Off-Exchange

Off-exchange %

100.0%

Week of: Jul 13, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$655.8M

Net income (FY): $-135.4M
EPS diluted: $-0.38

View

Filings

SEC Filings

Latest

6-K

Filed: Aug 6, 2026
This year: 4

View

Exempt Offerings

Offering

$62.1M

Filed: Dec 21, 2021

View

Earnings & Events

Earnings Calls

Last call

Aug 6, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
CRLBF	+12.0%	+10.1%	-22.6%	+23.0%	-35.8%
SPY	-0.1%	+4.1%	+12.4%	+3.4%	+13.3%
vs SPY	+12.1%	+6.0%	-35.0%	+19.6%	-49.1%

CRLBF · Cresco Labs Inc.

Price & Indicators

Up next

Equibles Rating

Guidance & track record

Technicals

Versus peers

At a glance

Performance